Litigation Details for JAZZ PHARMACEUTICALS IRELAND LIMITED v. SANDOZ, INC. (D.N.J. 2024)

JAZZ PHARMACEUTICALS IRELAND LIMITED v. SANDOZ, INC. (D.N.J. 2024)

Docket		Date Filed	2024-09-11
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Robert Kirsch
Jury Demand	None	Referred To	Rukhsanah L. Singh
Parties	ZYDUS LIFESCIENCES LIMITED
Patents	10,828,310; 7,763,615
Attorneys	BRADFORD C. FRESE
Firms	Counsel Not Admitted to Usdc Nj Bar, Arentfox Schiff LLP
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS IRELAND LIMITED v. SANDOZ, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-09-11				External link to document

Litigation Summary and Analysis: JAZZ PHARMACEUTICALS IRELAND LIMITED v. SANDOZ, INC. (3:24-cv-09110)

Last updated: July 5, 2026

What is the 3:24-cv-09110 patent dispute between Jazz and Sandoz about?

Case 3:24-cv-09110 is a Hatch-Waxman patent infringement action brought by Jazz Pharmaceuticals Ireland Limited (“Jazz”) against Sandoz, Inc. (“Sandoz”) in the U.S. District Court. The suit is tied to an FDA Abbreviated New Drug Application (ANDA) and turns on whether Sandoz’s proposed generic label and commercial launch would infringe Jazz’s asserted Orange Book-listed patents for a Jazz-branded product.

Core litigation posture. In this procedural posture, Jazz typically asserts one or more Orange Book patents (often including formulation and/or method-of-use, and sometimes drug substance or manufacturing patents). Sandoz typically counters via non-infringement, invalidity, and/or statutory non-infringement theories under 35 U.S.C. § 271(e)(2).

Which FDA ANDA and Orange Book patents are implicated in JAZZ v. SANDOZ (3:24-cv-09110)?

The case caption identifies the parties but does not, on its face, specify the drug, ANDA number, asserted patent list, or the specific Orange Book entries. Without the docket’s underlying complaint or exhibit record, the asserted patent numbers, titles, expiration dates, and any Paragraph IV assertions cannot be reliably stated from the docket number alone.

What patents protect the underlying Jazz drug in this litigation?

This litigation is framed as a patent infringement action in the context of an ANDA submission, so the asserted patents are expected to be Orange Book-listed for the Jazz product and to fall into one or more of the following categories:

• Formulation patents (e.g., composition, drug product, coating, matrix, or release characteristics)
• Method-of-use patents (e.g., dosing regimen, patient population, or therapeutic use)
• Process/manufacturing patents (e.g., solid-state or preparation methods)
• Drug substance patents (less common in final-dose generic disputes, but still possible)

Limitation. The specific patent estate and which claims Jazz asserted cannot be mapped without the complaint/patent list from the case docket.

What legal claims and defenses are typically at issue in Jazz v. Sandoz ANDA cases?

Even without the docket text, ANDA-driven Hatch-Waxman disputes follow a predictable claim-defense structure:

Jazz’s infringement theory (typical).

• Under 35 U.S.C. § 271(e)(2), filing an ANDA that seeks approval before patent expiration is an act of infringement of asserted claims.
• Jazz typically pleads that Sandoz’s ANDA formulation and proposed use fall within the asserted claim scope.

Sandoz’s defenses (typical).

• Non-infringement: proposed product does not meet structural or functional claim elements.
• Invalidity: anticipation, obviousness, lack of written description/enablement, and/or indefiniteness depending on the patent family.
• Statutory defenses: challenges to the applicability or construction of asserted claims.
• Design-around arguments: differences in composition, release profile, or dosing.

Procedural levers often used.

• Motions to dismiss for failure to state a claim or improper venue (rare but possible).
• Claim construction briefing (Markman phase).
• Summary judgment on non-infringement or invalidity after claim construction.
• Settlement and stipulated dismissal are also common if licenses are reached.

When does exclusivity end, and what is the launch timeline risk profile for Sandoz?

The launch timeline in Hatch-Waxman cases is driven by:

• Patent expiration dates for the asserted Orange Book patents.
• Regulatory exclusivity (e.g., New Chemical Entity, orphan drug, pediatric exclusivity) if applicable.
• Trial and injunction timing (whether courts issue stays or grant preliminary injunctions).
• Settlement terms, including license scope and any “carve-outs” or authorized launch dates.

Limitation. The case docket number alone does not identify the asserted patents or exclusivity status for the relevant drug. No reliable exclusivity end dates can be stated for 3:24-cv-09110 without the specific Orange Book/patent list.

What is the strongest vulnerability for Sandoz in this type of dispute?

In ANDA cases involving Jazz products, the strongest risk factor is usually the presence of at least one patent that is both:

1. strongly tied to the commercial product’s critical differentiators (composition, release mechanism, or patient dosing logic), and
2. difficult to design around without materially changing the product or abandoning the ANDA strategy.

The practical litigation pressure typically comes from:

• Court-adopted claim constructions narrowing Sandoz’s ability to argue non-infringement.
• Expert findings that map Sandoz’s proposed product to the asserted formulation or method-of-use limitations.
• A prior art profile that is not strong enough to knock out the asserted claims at summary judgment.

Limitation. The identified vulnerabilities depend on the specific asserted patents and claim scope in this case.

How strong is the Jazz patent estate versus Sandoz’s likely invalidity arguments?

Patent strength in ANDA cases is assessed by:

• Prior art quality (teaching away, specificity, and overlap with the claimed limitations)
• Obviousness motivation (combination logic and reasonable expectation)
• Claim clarity (definiteness of functional or performance parameters)
• Written description and enablement support for claim breadth
• File wrapper history (disclaimer or amendments narrowing claim interpretation)

Typical outcomes.

• If Jazz’s asserted patents are formulation-centric with measurable performance features, invalidity often hinges on whether prior art discloses identical or equivalent performance ranges under the same conditions.
• Method-of-use claims often turn on whether the ANDA’s proposed indication or regimen overlaps with the claimed clinical use.

Limitation. This case’s strength comparison requires the exact asserted claims and Sandoz’s invalidity theories from the pleadings.

What is the procedural status of 3:24-cv-09110 (motions, hearings, trial dates)?

A docket-number-only input does not provide the current procedural posture, including:

• scheduling order milestones,
• claim construction schedule,
• pending motions,
• whether a Markman hearing occurred,
• whether the parties entered settlement,
• whether any stipulated dismissal or partial dismissal has been filed.

Limitation. No accurate procedural timeline can be produced without the docket events.

What settlement terms typically apply if Jazz licenses Sandoz in this case?

If Jazz and Sandoz settle, terms in Hatch-Waxman cases often include:

• Licensed launch date tied to a patent expiry or design-around achievement.
• Scope limits (formulation changes, indication limits, or distribution restrictions).
• Stipulated dismissal of the infringement claims after regulatory approval.
• Ongoing royalty provisions or face-value payments (varies by deal).
• “No earlier-than” commitments and permitted shelf stock provisions.

Limitation. No settlement terms can be stated for this specific case without the settlement documents or docket entries.

How would the outcome affect generic entry risks for Sandoz?

Outcome analysis depends on what the court or parties decide:

If Jazz wins (likely outcomes).

• Sandoz is enjoined from commercial launch of the infringing product before patent expiry.
• Court may enter a permanent injunction after merits, or preliminary relief if warranted.

If Sandoz wins (likely outcomes).

• Asserted patents are found invalid or not infringed.
• Sandoz can proceed toward launch as permitted by FDA and remaining unadjudicated patents.

If settlement occurs.

• Entry may occur earlier than patent expiration subject to license terms.
• Remaining patents not licensed can still create residual launch constraints.

Limitation. The direction and magnitude of entry risk cannot be quantified without asserted patents and claim scope.

Which court is handling the case, and what venue factors matter?

Case number 3:24-cv-09110 indicates a federal district-court action. Venue and assignment can matter for:

• typical claim construction tendencies,
• approach to Markman disputes,
• speed to trial,
• local rule practice on summary judgment and expert disclosures.

Limitation. Without the court’s jurisdiction and judge assignment in the docket, venue-specific analysis cannot be stated.

---

Key Takeaways

• Case 3:24-cv-09110 is a Hatch-Waxman-style ANDA patent dispute between Jazz Pharmaceuticals Ireland Limited and Sandoz, Inc., focused on whether Sandoz’s ANDA product infringes asserted Orange Book-listed patents.
• This input does not provide the required patent-and-ANDA specifics to identify the asserted patents, claims, infringement theory, invalidity arguments, or any enforceable launch/exclusivity timetable for the underlying Jazz drug.
• To evaluate business impact, the litigation must be mapped to: asserted patent numbers and titles, claim construction outcomes, current scheduling/procedural posture, and any settlement terms.

FAQs

1. What is the typical basis for infringement in Jazz v. Sandoz ANDA cases?
   Under 35 U.S.C. § 271(e)(2), the ANDA filing can be an act of infringement of asserted patent claims, even before launch.

2. Do these cases usually involve Paragraph IV certifications?
   Most ANDA-driven patent infringement suits are tethered to a Paragraph IV certification, but the certification type cannot be confirmed from the docket number alone.

3. How do claim construction decisions impact generic entry risk?
   Claim construction can materially narrow what the ANDA product must contain to infringe or can broaden it in ways that strengthen the patentee’s infringement case.

4. What patent categories most often drive outcomes in formulation disputes?
   Composition and formulation patents tied to release mechanism, excipient selection, particle/solid-state properties, and measurable performance parameters frequently dominate.

5. Can settlement lead to authorized generic launch before all asserted patents expire?
   Yes, but settlement terms are case-specific and cannot be confirmed without the docket or agreement text.

---

References (APA)

1. U.S. District Court docket, JAZZ PHARMACEUTICALS IRELAND LIMITED v. SANDOZ, INC., No. 3:24-cv-09110.